IMMURON Ltd/S (NASDAQ:IMRN) has been given a $20.00 target price by HC Wainwright in a note issued to investors on Tuesday, May 29th. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price objective would suggest a potential upside of 109.10% from the stock’s current price.
A number of other brokerages also recently weighed in on IMRN. Zacks Investment Research downgraded shares of IMMURON Ltd/S from a “buy” rating to a “hold” rating in a research report on Thursday, March 22nd. ValuEngine downgraded shares of IMMURON Ltd/S from a “buy” rating to a “hold” rating in a research report on Monday, April 2nd.
Shares of NASDAQ IMRN traded up $0.24 during mid-day trading on Tuesday, hitting $9.56. The company’s stock had a trading volume of 5,930 shares, compared to its average volume of 9,155. IMMURON Ltd/S has a one year low of $4.47 and a one year high of $16.70.
Immuron Limited, a biopharmaceutical company, focuses on the research and development of polyclonal antibodies for the treatment and prevention of various diseases in Australia and internationally. The company operates through Research and Development, and HyperImmune Products segments. It has a technology platform that produces antibodies to treat various diseases, including infectious diseases, cancers, and chronic inflammatory diseases.
Receive News & Ratings for IMMURON Ltd/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMMURON Ltd/S and related companies with MarketBeat.com's FREE daily email newsletter.